MGI Pharma and Helsinn Healthcare plan to file a new marketing application for the nausea drug Aloxi after two late-stage trials demonstrated its effectiveness against nausea and vomiting after surgery. The data demonstrated a complete response by patients up to 72 hours after surgery. The drug is already approved to prevent nausea and vomiting after chemotherapy.
- here's the AP report on the new data